Science news and discoveries from the Mass General Research Institute
Bench PressBench PressBench PressBench Press
  • Home
  • About
  • Research
    • COVID-19
    • Brain
    • Heart
    • Cancer
    • More…
  • Communicating Science
  • Events
  • Subscribe

Blog

Ketamine Approval Offers New Hope for Treatment-Resistant Depression, But Questions Remain

By mghresearch | Depression, Psychiatry | 0 comment | 26 March, 2019 | 0

While the FDA’s approval of the first ketamine-based drug for treatment-resistant depression is encouraging, there are still a lot of details to work out, says Cristina Cusin, MD.

Research Shows Ketamine Could Be an Answer for Treatment-Resistant Depression

By MGH Research Institute | Depression, Psychiatry | 0 comment | 25 October, 2018 | 0

A Mass General research team is working to identify the ideal dosages for treating depression with ketamine.

Categories

Social

Tags

adolescents aging allergies ALS artificial intelligence brain health cancer treatments child health cholera clinical research clinical trials community health coronavirus dementia diagnostic tools diversity exercise Harvard health disparities heart attacks heart disease heart failure heart month hypertension image contest innovation internships kidney disease machine learning martinos center memory mental health microbiome Munn Center for Nursing Research nursing PET imaging postdocs public health Ragon Institute rare diseases researchers science writing sleep women's health women in medicine

Copyright 2020
Mass General Research Institute
All Rights Reserved

SUBSCRIBE TO BENCH PRESS


Contact

Mass General Research Institute
125 Nashua St.
Boston, MA 02114
617-724-0200
researchinstitute@mgh.harvard.edu
M-F: 9:00 am - 5:00 pm
  • Home
  • About
  • Research
    • Brain
    • Cancer
    • Heart
  • Communicating Science
  • Events
  • Home
  • About
  • Research
    • Brain
    • Cancer
    • Heart
    • More…
  • Communicating Science
  • Events
Bench Press